Drug Trial Radar · NCT06136624
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,310
Planned (sponsor's estimate)
Start
Dec 31, 2023
Primary completion
Nov 30, 2028
Study completion Mar 29, 2030
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Nov 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) in participants with mCRPC previously treated with next-generation hormonal agent (NHA) and taxane-based chemotherapy. It is hypothesized that opevesostat is superior with respect to OS in androgen receptor ligand binding domain (AR LBD) mutation-negative and -positive participants.
Conditions
- Prostate Cancer Metastatic
Interventions
OpevesostatDrug
Administered orally
Abiraterone acetateDrug
Administered orally
EnzalutamideDrug
Administered orally
HydrocortisoneDrug
Administered orally or IM as a rescue medication
Fludrocortisone acetateDrug
Administered orally
PrednisoneDrug
Administered orally as a rescue medication
DexamethasoneDrug
Administered orally as rescue medication
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS) in Androgen Receptor Ligand Binding Domain (AR LBD) Mutation-Positive ParticipantsTime frame: Up to ~54 months
- OS in AR LBD Mutation-Negative ParticipantsTime frame: Up to ~54 months
Locations
288 sites in 36 countries. Site status is shown where the registry gives one.
University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0040)
Orange, California · Completed
Stanford Cancer Center ( Site 0036)
Palo Alto, California · Recruiting
Kaiser Permanente Riverside Medical Center ( Site 0099)
Riverside, California · Recruiting
Anschutz Cancer Pavilion ( Site 0046)
Aurora, Colorado · Recruiting
University of Colorado Health - Highlands Ranch Hospital ( Site 0111)
Highlands Ranch, Colorado · Recruiting
Colorado Clinical Research ( Site 0067)
Lakewood, Colorado · Completed
University of Colorado Health - Lone Tree Medical Center ( Site 0112)
Lone Tree, Colorado · Recruiting
Yale-New Haven Hospital-Yale Cancer Center ( Site 0064)
New Haven, Connecticut · Recruiting
Florida Cancer Specialists - South ( Site 7003)
Fort Myers, Florida · Completed
Bruce W. Carter Veterans Affairs Medical Center ( Site 0082)
Miami, Florida · Completed
University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 0051)
Miami, Florida · Recruiting
University of Illinois at Chicago ( Site 0105)
Chicago, Illinois · Recruiting
University of Chicago Medical Center ( Site 0045)
Chicago, Illinois · Recruiting
University of Iowa ( Site 0047)
Iowa City, Iowa · Completed
University of Kentucky Chandler Medical Center ( Site 0048)
Lexington, Kentucky · Completed
Ochsner Clinic Foundation ( Site 0108)
New Orleans, Louisiana · Completed
Baltimore Veterans Affairs Medical Center ( Site 0069)
Baltimore, Maryland · Recruiting
Greenebaum Comprehensive Cancer Center ( Site 0049)
Baltimore, Maryland · Recruiting
Henry Ford Hospital ( Site 0015)
Detroit, Michigan · Completed
Avera Cancer Institute - Marshall ( Site 0122)
Marshall, Minnesota · Recruiting
M Health Fairview Clinics and Surgery Center ( Site 0019)
Minneapolis, Minnesota · Recruiting
Metro-Minnesota Community Clinical Oncology ( Site 0014)
Saint Louis Park, Minnesota · Active not recruiting
Hattiesburg Clinic Hematology/Oncology ( Site 0120)
Hattiesburg, Mississippi · Recruiting
Washington University School of Medicine-Internal Medicine/Oncology ( Site 0062)
St Louis, Missouri · Recruiting
University Of Nebraska Medical Center-Oncology/Hematology ( Site 0095)
Omaha, Nebraska · Recruiting
Comprehensive Cancer Centers of Nevada ( Site 0010)
Las Vegas, Nevada · Recruiting
Atlantic Health System Morristown Medical Center ( Site 0115)
Morristown, New Jersey · Recruiting
Rutgers Cancer Institute of New Jersey ( Site 0033)
New Brunswick, New Jersey · Completed
James J. Peters VA Medical Center ( Site 0088)
The Bronx, New York · Recruiting
University Hospitals Cleveland Medical Center ( Site 0043)
Cleveland, Ohio · Recruiting
Oregon Health and Science University ( Site 0028)
Portland, Oregon · Completed
VA Portland Health Care System ( Site 0058)
Portland, Oregon · Recruiting
AHN Allegheny General Hospital ( Site 0001)
Pittsburgh, Pennsylvania · Completed
Ralph H. Johnson VA Health Care System (RHJVAHCS)-Urology ( Site 0083)
Charleston, South Carolina · Completed
Avera Cancer Institute - Aberdeen ( Site 0123)
Aberdeen, South Dakota · Recruiting
Avera Cancer Institute - Mitchell ( Site 0121)
Mitchell, South Dakota · Recruiting
Avera Cancer Institute - Pierre ( Site 0118)
Pierre, South Dakota · Recruiting
Avera Cancer Institute- Research ( Site 0094)
Sioux Falls, South Dakota · Recruiting
Avera Cancer Institute - Yankton ( Site 0117)
Yankton, South Dakota · Recruiting
SCRI Oncology Partners ( Site 7000)
Nashville, Tennessee · Recruiting
Showing 40 of 288 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.